丙型肝炎病毒C33_c单克隆抗体的研制和鉴定

用丙型肝炎病毒重组蛋白Ｃ３３_ｃ抗原免疫ＢＡＬＢ／ｃ小鼠,运用杂交瘤技术成功地建立了７株能稳定分泌抗Ｃ３３_ｃ单克隆抗体的杂交瘤细胞１Ｈ６Ｄ２、２Ｇ１Ａ６、３Ａ４Ａ８、３Ｅ３Ｅ７、４Ｇ１２Ｃ１０、４Ａ１０Ｃ２、５Ｆ４Ｂ６．试验结果表明,７株ＭｃＡｂｓ具有良好的ＨＣＶ特异性,间接ＥＬＩＳＡ法测得小鼠腹水ＭｃＡｂ效价为１：１０￣４－１：４×１０￣４;竞争抑制实验和相加指数测定证实７株ＭｃＡｂｓ识别相关的抗原表位;７株ＭｃＡｂｓ中１株为ＩｇＭ（５Ｆ４Ｂ６）,其它６株为ＩｇＧ（２ａ）。     

P物质对大鼠DRG神经元胞体膜的作用

本文在大鼠ＤＲＧ神经元标本上应用细胞内记录,以确定ＳＰ对ＤＲＧ细胞的膜反应及其可能的离子机制。实验所测ＤＲＧ细胞静息膜电位为－５８．９±８．２ｍＶ（Ｘ±ＳＥ,ｎ＝８１）。传导速度：Ａ_（α／β）细胞为２０．４±４．８ｍ／ｓ（Ｘ±ＳＥ）,范围１４．１－２８．７ｍ／ｓ（４７／６０）;Ａδ及Ｃ类细胞为９．８±５．２ｍ／ｓ,范围１．２－１３．７ｍ／ｓ（１３／６０）。浴槽滴加ＳＰ（１０￣（－７）－３×１０￣（－４）ｍｏｌ／Ｌ）在大多数细胞可引起明显的膜去极化反应（５６／６０）。少数细胞对ＳＰ无反应（４／６０）。在ＳＰ去极化期间膜电导值有所增加,从平均值２．７２×１０￣（－８）ｍｈｏ增加２４．６％（ｎ＝３）。所测逆转电位值在＋４０－＋５０ｍＶ之间（ｎ＝３）。浊流平衡液（ＢＳＳ）中ＮａＣｌ以氯化胆碱置代,或用含ＴＴＸ（１０￣（－５）ｍｏｌ／Ｌ）的ＢＳＳ灌流,可使ＳＰ－去极化幅值大大减小但不能完全消除。而高（２０ｍｍｏｌ／Ｌ）和低（０ｍｍｏｌ／Ｌ）Ｃａ￣（２＋）的ＢＳＳ灌流时,使ＳＰ－去极化幅值相应的增加和降低。用含１０￣（－４）ｍｏｌ／ＬＣｄ￣（２＋）及１０￣（－２）ｍｏｌ／ＬＴＥＡ的ＢＳＳ灌流,均使ＳＰ－去极化明显减小。     

南方鲇碱性磷酸酶的分离纯化及部分性质的研究

用正丁醇抽提,硫酸铵分级沉淀,ＤＥＡＥ－纤维素和ＳｅｐｈａｃｒｙｌＳ－２００柱层析,从南方鲇（Ｓｉｌｕｒｕｓ　ｍｅｒｉｄｉｏｎａｌｉｓ　Ｃｈｅｎ）肠粘膜中提取出碱性磷酸酶（ＡＫＰ）。提纯倍数为３９．５０倍,比活为６８．３５μ／ｍｇ蛋白,提取酶液经ＰＡＧＥ和ＳＤＳ－ＰＡＧＥ只呈现一条区带。该酶的分子量为１３２１４０,Ｎ末端氨基酸为门冬氨酸,最适ｐＨ为１０．１０,７．５＞ｐＨ＞１１．５时不稳定,最适温度为４０℃左右,对热不很稳定,以磷酸苯二钠为底物其Ｋ_ｍ值为１．７２×１０~（－３）ｍｏｌ／Ｌ。Ｍｇ~（２＋）、Ｍｎ~（２＋）为该酶的激活剂,ＫＨ_２ＰＯ_４、Ｌ－ＣｙＳ、ＭＥ、ＤＦＰ、ＥＤＴＡ－Ｎａ_２为抑制剂。选用ＫＨ_２ＰＯ_４和ＤＦＰ作抑制类型的判断,结果表明,ＫＨ_２ＰＯ_４属竞争性掏剂,其抑制常数为２．３ｍｍｏｌ／Ｌ;ＤＦＰ为非竞争性抑制剂,抑制常数为１．０５ｍｍｏｌ／Ｌ。     

P物质对GABAA和GABAB受体介导的DRG神经元膜反应的调制作用

实验在幼年大鼠ＤＲＧ标本上进行。应用细胞内记录观察了ＳＰ对ＧＡＢＡ反应的调制作用。结果证明：（１）单独滴加ＳＰ（５×１０（－６）－４×１０（－５）ｍｏｌ／Ｌ）或浴槽灌流ＳＰ（１０（－６）－５×１０（－６）ｍｏｌ／Ｌ）不引起膜电位的改变或仅有轻微的去极化,但却能使ＧＡＢＡ引起的去极化反应减小５０．８±２０．２％（±ＳＤ）（２０／３０）;（２）单独滴加ＳＰ可使多数受检细胞ＡＰＤ５０延长２８．７±９．１％（±ＳＤ）（１０／１８）;（３）在预加ＳＰ后,能使ｂａｃｌｏｆｅｎ所引起的ＡＰＤ５０缩短效应（２０．６±２．９％,±ＳＤ）完全消除（４／１２）或翻转成ＡＰＤ（５０）延长１９．３±８．９％（±ＳＤ）（８／１２）;（４）预加ＧＡＢＡＢ受体激动剂ｂａｃｌｏｆｅｎ（１０（－４）－１０（－３）ｍｏｌ／Ｌ）３０—９０ｓ后明显地抑制ｍｕｓｃｉｍｏｌ（１０－４－１０－３ｍｏｌ／Ｌ）引起的去极化反应,其抑制效应达５４．４±１８．８％（±ＳＤ）（１７／２０）。由于ＤＲＧ神经元的胞体通常可用来作为研究初级传入终末的模型,因而本文实验结果提示：介导伤害性刺激信息的Ｐ物质在背角的释放,可能作用于初级传入终末,从而产生对抗ＧＡＢＡ介导的突触     

用核酸免疫技术制备抗丙肝病毒C区单克隆抗体

用丙肝病毒Ｃ＋Ｅ１区真核表达质粒ｐｃＤＮＡ－ＨＣＶ／Ｃ＋Ｅ１按４００ｕｇ／只剂量免疫ＢＡＬＢ／Ｃ小鼠,１４周后同一剂量再加强免疫一次。加强免疫后２周,在５０％ＰＥＧ１４５０介导下将脾细胞与ＳＰ２／０小鼠骨髓瘤细胞（５１）融合。实验结果融合率达５４．３％（３１３／５７６）。阳性率为５．４％（１７”３１３）。克隆化后得到６株稳定分泌抗丙肝病毒Ｃ区单克隆抗体杂交瘤细胞株。这６株杂交瘤均产生ＩｇＭ抗体,接种ＢＡＬＢ／Ｃ小鼠后产生腹水的效价为１６４－１３２０（ＥＬＩＳＡ）。     

盐生杜氏藻甘油-3-磷酸脱氢酶的分离纯化及其特性的研究

利用ＰＥＧ分级,ＤＥＡＥ离子交换层析,ＢｌｕｅＳｅｐｈａｒｏｓｅ拟亲和层析,ＭｏｎｏＱ离子交换层析等手段,分离纯化盐生杜氏藻（Ｄｕｎａｌｉｅｌａｓａｌｉｎａ（Ｄｕｎａｌ）Ｔｅｏｄ．）甘油三磷酸（Ｇ３Ｐ）脱氢酶（ＥＣ１．１．１．８）,得到比活为１２．６Ｕ／ｍｇ的电泳纯的酶,并对此酶的生化特性进行了研究。４％～２０％非变性聚丙烯酰胺梯度凝胶电泳测得全酶分子量约为２７０ｋＤ,ＳＤＳＰＡＧＥ表明该酶只有一种分子量约为６５ｋＤ的亚基,据此推测该酶应为同四聚体。酶催化磷酸二羟丙酮（ＤＨＡＰ）还原的最适ｐＨ值为７．５,催化Ｇ３Ｐ脱氢的最适ｐＨ值为１０。该酶对４个底物还原型辅酶Ⅰ（ＮＡＤＨ）,二磷酸吡啶核苷酸（ＤＨＡＰ）,辅酶Ⅰ（ＮＡＤ）,Ｇ３Ｐ的表观Ｋｍ值分别为６３μｍｏｌ／Ｌ,２７２μｍｏｌ／Ｌ,１．５３ｍｍｏｌ／Ｌ,６．５２ｍｍｏｌ／Ｌ。该酶在保存过程中易失活。ＮＡＤＨ能降低酶失活的速度,而ＮＡＤ则不然。低浓度ＮａＣｌ对酶略有保护作用,但高浓度ＮａＣｌ加快酶的失活,且浓度越高效应越明显。     

β—环糊精对苯丙氨酸解氨酶反应影响的研究

在含有较高浓度底物反式肉桂酸（ｔｒａｎｓ－ｃｉｎｎａｍｉｃ ａｃｉｄ,ＣＡ）和氨反应介质中,研究了β－环糊精（β－ＣＤ）对红醇母苯丙氨酸解氨酶（Ｐｈｅｎｙｌａｌａｎｉｎｅ ａｍｍｏｎｉａ－ｌｙａｓｅ,ＰＡＬ,ＥＣ４．３．１．５）催化反应的影响。加入适量β－ＣＤ可以克服高浓度ＣＡ对ＰＡＬ活性的抑制作用,显著增加产物Ｌ－苯丙氨酸（Ｌ－ｐｈｅ）的产量,β－ＣＤ最适用量随ＣＡ浓度升高而增加,其摩尔数量约为     

马尾松成熟合子胚的体细胞胚胎发生和植株再生

采用马尾松（Ｐｉｎｕｓｍ ａｓｓｏｎｉａｎａ Ｌａｍ ｂ．）成熟合子胚为起始外植体,在含２,４－Ｄ １０ ｍ ｇ／Ｌ,ＫＴ和ＢＡ 各４ ｍ ｇ／Ｌ的ＤＣＲ培养基上得到胚发生培养物。将白色半透明的愈伤组织（含早期原胚）在含２,４－Ｄ１．０ ｍ ｇ／Ｌ,ＫＴ和ＢＡ 各０．４ ｍ ｇ／Ｌ的ＤＣＲ培养基上保持并增殖。在附加９０００ ｍ ｇ／Ｌ肌醇的ＤＣＲ高渗培养基上得到粗壮的后期原胚。ＡＢＡ 和活性炭同时使用能促进子叶胚的形成,最高频率为３５．１％ 。在无激素培养基上,成熟体细胞胚萌发并进一步形成完整小植株     

缢蛏碱性磷酸酶胍溶液中分子折叠与活力变化研究

报道了缢蛏碱性磷酸酶（简称ＡＬＰ）经不同浓度盐酸胍处理时酶的分子构象所发生的变化以及酶变化和失活的动力学过程。在胍中酶荧光发射峰强度下降,紫外差光谱在２４６ｎｍ和２８５ｎｍ处出现２个负峰,ＣＤ谱中酶的α螺旋度下降,且随浓度增大,变化程度也加大。动力学研究表明,酶在０．５ｍｏｌ／Ｌ、１．０ｍｏｌ／Ｌ、２．０ｍｏｌ／Ｌ３．０ｍｏｌ／Ｌ、４．０ｍｏｌ／Ｌ盐酸胍中的变性速度常数分别为３．２１×１０~（－４）ｓ~（－１）、６．３８×１０~（－４）ｓ~（－１）、２．１７×１０~（－３）ｓ~（－１）、２．３３×１０~（－３）ｓ~９－１）、５．１７×１０~（－３）ｓ~（－１）;而酶在相应盐酸胍中的失活速度常数分别为２．３３×１０~（－４）ｓ~（－１）、３．５７×１０~（－４）ｓ~（－１）、５．８６×１０~（－４）ｓ~（－１）、１．１４×１０~（－３）ｓ~（－１）、３．４５×１０~（－３）ｓ~（－１）;表现为失活与构象伸展变化基本平行。     

香椿的组织培养和玻璃苗的防止

１植物名称香椿（Ｔｏｏｎａｓｉｎｅｎｓｉｓ）。２材料类别（１）种子发芽３～５ｄ后的下胚轴及带少许下胚轴的子叶;（２）当年生半木质化的腋芽茎段。３培养条件芽诱导及增殖培养,以ＭＳ为基本培养基,蔗糖３０ｇ·Ｌ~（－１）,琼脂０．５％,附加激素（单位ｍｇ·Ｌ~（－１））：（１）６－ＢＡ０．２;（２）６－ＢＡ０．２、ＧＡ_３２．０;（３）ＩＡＡ０．１、６ＢＡ０．２;（４）ＺＴ０．２、ＧＡ_３２．０。诱导生根培养基为１／ＺＭＳ或仅含ＭＳ有机质（铁盐减半）,附加１．０ｍｇ·Ｌ~（－１）ＩＢＡ、１５ｇ·Ｌ~（－１）…     

Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells

Epstein-Barr virus (EBV) invasion of B-lymphocytes involves EBV gp350/220 binding to B-lymphocyte CR2. The anti-gp350 monoclonal antibody (mAb)-72A1 Fab inhibits this binding and therefore blocks EBV invasion of target cells. However, gp350/220 regions interacting with mAb 72A1 and involved in EBV invasion of target cells have not yet been identified. This work reports three gp350/220 regions, defined by peptide 11382, 11389, and 11416 sequences, that are involved in EBV binding to B-lymphocytes. Peptides 11382, 11389, and 11416 bound to CR2(+) but not to CR2(-) cells, inhibited EBV invasion of cord blood lymphocytes (CBLs), were recognized by mAb 72A1, and inhibited mAb 72A1 binding to EBV. Peptides 11382 and 11416 binding to peripheral blood lymphocytes (PBLs) induced interleukin-6 protein synthesis in these cells, this phenomenon being inhibited by mAb 72A1. The same behavior has been reported for gp350/220 binding to PBLs. Anti-peptide 11382, 11389, and 11416 antibodies inhibited EBV binding and EBV invasion of PBLs and CBLs. Peptide 11382, 11389, and 11416 sequences presented homology with the C3dg regions coming into contact with CR2 (C3dg and gp350 bound to similar CR2 regions). These peptides could be used in designing strategies against EBV infection.     

A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells

Bispecific antibody (BsAb) can physically cross-link immune cells to tumor cells, circumventing the proper structures for tumor cell-immune cell interactions and activating the cellular cytotoxic mechanisms. The optimal BsAb should target tumor cells with high affinity, but activate trigger molecules on cytotoxic cells by monovalent binding of Fab fragments. In the present study, a trivalent anti-erbB2/anti-CD16 BsAb was produced. This BsAb possesses bivalent arms specifically binding to the extracellular domain of erbB2 and monovalent Fab fragment redirecting NK cells. The recombinant protein could be expressed and purified from Escherichia coli as native proteins without refolding. It was fully functional in bispecific binding to SKBR3 and NK cells. The molecular size of this trivalent BsAb protein is larger than diabody and smaller than whole antibody and expected to have advantages for both high penetration of small antibody fragments and the slow circulation clearance of whole antibody. This novel protein may be an attractive target for further improvement and evaluation.     

转化相关蛋白p86的鉴定

以转化细胞Rat3-3免疫大鼠,获得单克隆抗体E5(MeAb E5)。其对应抗原耐热,是分子量为86kD的蛋白质(P86)。它在c-Ha-ras癌基因转化的细胞上均有较高的阳性表达,而在其相应的非转化细胞上含量甚微。以人工合成的反义c-Ha-ras寡聚核苷酸As-Ⅱ处理Rat3-3细胞,该细胞生长受抑(44.2％),,此对p86的表达亦降低(39.1％)。P86在五种人胃癌细胞系中均有较高表达,在原发胃癌及其转移灶中阳性率达82.6％。p86不仅是一种与C-Ha-ras转化相关的蛋白,而且为胃癌相关抗原。     

CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling

It was originally thought that the critical role of the CD40 ligand (CD40L) in normal and inflammatory immune responses was mainly mediated through its interaction with the classic receptor, CD40. However, data from CD40L(-/-) and CD40(-/-) mice suggest that the CD40L-induced inflammatory immune response involves at least one other receptor. This hypothesis is supported by the fact that CD40L stabilizes arterial thrombi through an alphaIIbbeta3-dependent mechanism. Here we provide evidence that soluble CD40L (sCD40L) binds to cells of the undifferentiated human monocytic U937 cell line in a CD40- and alphaIIbbeta3-independent manner. Binding of sCD40L to U937 cells was inhibited by anti-CD40L monoclonal antibody 5C8, anti-alpha5beta1 monoclonal antibody P1D6, and soluble alpha5beta1. The direct binding of sCD40L to purified alpha5beta1 was confirmed in a solid phase binding assay. Binding of sCD40L to alpha5beta1 was modulated by the form of alpha5beta1 expressed on the cell surface as the activation of alpha5beta1 by Mn(2+) or dithiothreitol resulted in the loss of sCD40L binding. Moreover, sCD40L induced the translocation of alpha5beta1 to the Triton X-100-insoluble fraction of U937 cells, the rapid activation of the MAPK pathways ERK1/2, and interleukin-8 gene expression. The binding of sCD40L to CD40 on BJAB cells, an alpha5beta1-negative B cell line, and the resulting activation of ERK1/2 was not inhibited by soluble alpha5beta1, suggesting that sCD40L can bind concomitantly to both receptors. These results document the existence of novel CD40L-dependent pathways of physiological relevance for cells expressing multiple receptors (CD40, alpha5beta1, and alphaIIbbeta3) for CD40L.     

Nanocell targeting using engineered bispecific antibodies

There are many design formats for bispecific antibodies (BsAbs), and the best design choice is highly dependent on the final application. Our aim was to engineer BsAbs to target a novel nanocell (EnGeneIC Delivery Vehicle or EDV^TMnanocell) to the epidermal growth factor receptor (EGFR). EDV^TMnanocells are coated with lipopolysaccharide (LPS), and BsAb designs incorporated single chain Fv (scFv) fragments derived from an anti-LPS antibody (1H10) and an anti-EGFR antibody, ABX-EGF. We engineered various BsAb formats with monovalent or bivalent binding arms and linked scFv fragments via either glycine-serine (G4S) or Fc-linkers. Binding analyses utilizing ELISA, surface plasmon resonance, bio-layer interferometry, flow cytometry and fluorescence microscopy showed that binding to LPS and to either soluble recombinant EGFR or MDA-MB-468 cells expressing EGFR, was conserved for all construct designs. However, the Fc-linked BsAbs led to nanocell clumping upon binding to EDV^TMnanocells. Clumping was eliminated when additional disulfide bonds were incorporated into the scFv components of the BsAbs, but this resulted in lower BsAb expression. The G4S-linked tandem scFv BsAb format was the optimal design with respect to EDV binding and expression yield. Doxorubicin-loaded EDV^TMnanocells actively targeted with tandem scFv BsAb in vivo to MDA-MB-468-derived tumors in mouse xenograft models enhanced tumor regression by 40% compared to passively targeted EDV^TMnanocells. BsAbs therefore provide a functional means to deliver EDV^TMnanocells to target cells.     

双特异性抗体构建在肿瘤临床治疗中的应用

双特异性抗体(Bispecific antibody,BsAb)是具有两个不同抗原结合位点的抗体,可分为含Fc段和不含Fc段的BsAb,不同结构的BsAb具有不同的特点和应用领域。相比于传统的单克隆抗体,BsAb的灵敏度和特异性更高。更重要的是,BsAb具有募集免疫细胞、双重阻断信号通路等功能,在免疫诊断和治疗中扮演重要角色。随着全球环境的恶化以及人们生活习惯的不规律,肿瘤的发病率越来越高,成为仅次于心脑血管疾病的全球第二大致死疾病,全球每年有1200万新发癌症病例。肿瘤的治疗手段包括手术切除、放化疗和靶向治疗等。肿瘤免疫疗法是近几年新兴的治疗方法,其通过激发自身免疫系统的能力来清除肿瘤细胞。传统的单抗药物虽在肿瘤靶向治疗和免疫治疗中取得了一定的疗效,但肿瘤具有高度的异质性和可塑性,常常引发肿瘤耐药性的出现。双特异性抗体能够同时靶向多个靶点,目前已用于肿瘤的临床治疗,并取得了一定的治疗效果。文中就双特异性抗体在肿瘤临床治疗中的研究进展和应用作一综述。     

A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy

Ephrin receptor A10 (EphA10), a transmembrane receptor that binds to ephrin, is a newly identified breast cancer marker protein that has also been detected in HER2-negative tissue. In this study, we report creation of a novel bispecific antibody (BsAb) binding both EphA10 and CD3, thereby forming a bridge between antigens expressed on both tumor and immune cells and promoting recognition of tumor cells by immune cells and redirection of cytotoxic T cells (CTL). This BsAb (EphA10/CD3) was expressed in supernatants of BsAb gene-transfected cells as monomeric and dimeric molecules. Redirected T-cell lysis was observed when monomeric and dimeric BsAb were added to EphA10-overexpressing tumor cells in vitro. Furthermore, dimeric BsAb (EphA10/CD3) was more cytotoxic than monomeric BsAb, with efficient tumor cell lysis elicited by lower concentrations (≤10⁻¹ μg/mL) and a lower effector to target (E/T) cell ratio (E/T = 2.5). Dimeric BsAb (EphA10/CD3) also showed significant anti-tumor effects in human xenograft mouse models. Together, these results revealed opportunities to redirect the activity of CTL towards tumor cells that express EphA10 using the BsAb (EphA10/CD3), which could be tested in future clinical trials as a novel and potent therapeutic for breast cancer tumors.     

Nanocell targeting using engineered bispecific antibodies

There are many design formats for bispecific antibodies (BsAbs), and the best design choice is highly dependent on the final application. Our aim was to engineer BsAbs to target a novel nanocell (EnGeneIC Delivery Vehicle or EDV^TMnanocell) to the epidermal growth factor receptor (EGFR). EDV^TMnanocells are coated with lipopolysaccharide (LPS), and BsAb designs incorporated single chain Fv (scFv) fragments derived from an anti-LPS antibody (1H10) and an anti-EGFR antibody, ABX-EGF. We engineered various BsAb formats with monovalent or bivalent binding arms and linked scFv fragments via either glycine-serine (G4S) or Fc-linkers. Binding analyses utilizing ELISA, surface plasmon resonance, bio-layer interferometry, flow cytometry and fluorescence microscopy showed that binding to LPS and to either soluble recombinant EGFR or MDA-MB-468 cells expressing EGFR, was conserved for all construct designs. However, the Fc-linked BsAbs led to nanocell clumping upon binding to EDV^TMnanocells. Clumping was eliminated when additional disulfide bonds were incorporated into the scFv components of the BsAbs, but this resulted in lower BsAb expression. The G4S-linked tandem scFv BsAb format was the optimal design with respect to EDV binding and expression yield. Doxorubicin-loaded EDV^TMnanocells actively targeted with tandem scFv BsAb in vivo to MDA-MB-468-derived tumors in mouse xenograft models enhanced tumor regression by 40% compared to passively targeted EDV^TMnanocells. BsAbs therefore provide a functional means to deliver EDV^TMnanocells to target cells.     

Differential spontaneous killing of human and murine tumour cell lines by leucocyte subpopulations from carp peripheral blood leucocytes

Cell populations from carp (Cyprinus carpio L.) peripheral blood leucocytes (PBLs) were examined for nonspecific cytotoxicities. By using monoclonal antibodies (MAbs) against carp thrombocytes (TCL-HB8) and both neutrophils and monocytes (TCL-BE8), PBLs with a density of 1.08 g ml-1 were separated into three fractions: thrombocytes, a mixture of neutrophils and monocytes, and other cells (mainly lymphocytes), and the separated cells were tested for cytotoxic activities against mammalian tumour cell lines (K562, HeLa, P815 and Yac-1 cell). Consequently, the mixture of neutrophils and monocytes exhibited cytolysis against these target cells, whereas the lymphocyte-rich and thrombocyte fractions did not show any cytolysis. To isolate only neutrophils, which do not contain monocytes, the MAb (TCL-BE8) positive cells from PBLs with a density of 1.08-1.09 g ml-1 were separated. Pure isolated neutrophils showed cytotoxic activities against K562 cells, but not P815 cells. Furthermore, analysis of the cytolytic mechanisms indicated that killing of these cells depended on H2O2 or HOCl. These results suggest that both neutrophils and monocytes are effectors for nonspecific cytotoxicity in carp PBLs, and neutrophils may be distinct from monocytes in their reactivity in cytolysis, including target cell selectivity and/or target cell sensitivity, and the cytolytic pathway. In carp, cytotoxicity of target cells can be mediated by several populations of their leucocytes which have cytotoxic capacities with various recognition and cytolytic mechanisms.     

Role of immune cells in protection against and control of reovirus infection in neonatal mice.

We studied the role of T cells in resistance to reovirus intestinal and central nervous system infection. Transfer of reovirus-immune adult spleen cells protected neonatal mice from (i) lethal infection with reovirus serotype 3 Dearing (T3D, footpad inoculation) and serotype 3 clone 9 (T3C9, oral inoculation) and (ii) hydrocephalus caused by serotype 1 Lang (T1L, intracranial [i.c.] inoculation). Cell-mediated protection was not serotype specific. While immune cells protected against T1L i.c., they failed to protect against 1/5,000 of the dose of T3D i.c. Two types of experiments showed that both CD4 and CD8 T cells are involved in reovirus resistance. First, immune cell-mediated protection against T3D was abrogated by in vivo treatment with anti-CD4 monoclonal antibody (MAb) and significantly inhibited by in vivo treatment with anti-CD8 MAb. Second, T3C9-infected neonatal mice treated with anti-CD4 and/or anti-CD8 developed a novel disease phenotype, an oily hair syndrome, associated with severe hepatobiliary pathology and increased viral titer in heart and liver. Immune cells and an MAb to the cell attachment protein sigma 1 (MAb G5) protected by different mechanisms. Immune cells were more effective than sigma 1 MAb G5 at controlling primary replication, while sigma 1 MAb G5 was more effective than immune cells at inhibiting neural spread of virus. We conclude that both CD4 and CD8 T cells are important for reovirus resistance, that cells and antibody act preferentially at different stages in pathogenesis in vivo, and that adoptively transferred immune cells can protect both the central nervous system and intestine.